XL147 analogue

카탈로그 번호S1118 배치:S111802

인쇄

기술 자료

화학식

C₂₁H₁₆N₆O₂S₂

분자량

448.52

CAS 번호

956958-53-5

용해도 (25°C)*

시험관 내(In vitro)

DMSO

89 mg/mL (198.43 mM)

Water

Insoluble

Ethanol

Insoluble

생체 내(In Vivo) (개별적으로 순서대로 용매를 제품에 첨가하십시오.)

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml은 약간 용해되거나 불용해됨을 의미합니다.
* Selleck은 모든 화합물의 용해도를 자체적으로 테스트하며, 실제 용해도는 게시된 값과 약간 다를 수 있습니다. 이는 정상적인 현상이며, 약간의 배치 간 변동으로 인해 발생합니다.
* 실온 배송 (안정성 테스트 결과 이 제품은 냉각 조치 없이 배송될 수 있음을 보여줍니다.)

원액 준비

생물학적 활성

설명

XL147 analogue (SAR245408) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. This compound induces apoptosis. Phase 1/2.

표적

PI3Kγ (Cell-free assay)	PI3Kδ (Cell-free assay)	PI3Kα (Cell-free assay)	PI3Kβ (Cell-free assay)
23 nM	36 nM	39 nM	383 nM

시험관 내(In vitro)

XL147 analogue inhibits class I PI3K isoforms in an ATP-competitive manner. In a panel of HER2-overexpressing human breast cancer cell lines, treatment with this compound abrogates AKT and S6 phosphorylation but also induces the expression and phosphorylation of HER3 and other RTKs. In HER2⁺ cells, phosphorylation of HER3 is maintained by the HER2 tyrosine kinase, leading to partial recovery of phosphorylated AKT (pAKT) and thereby limiting the antitumor action of this chemical. In addition, knockdown of HER3 or treatment with the anti-HER2 agents trastuzumab or lapatinib sensitizes HER2⁺ breast cancer cells to this agent in vitro and in vivo. Treatment with this inhibitor inhibits the monolayer growth of all tested cell lines, including BT474, HCC1937 et al. in a dose-dependent manner. The main effect of this compound is inhibition of cell proliferation. It induces cell death at the concentration of 20 μM. Treatment with this chemical leads to dose-dependent inhibition of PI3K. Consistent with the inhibition of cell proliferation, it induces a reduction in cyclin D1 and pRB and an increase in levels of the CDK inhibitor p27^KIPI but no detectable change in levels off total or cleaved poly (ADP-ribose) polymerase (PARP). Treatment with this agent leads to a dose-dependent reduction in pAKT^S473/T308 and pS6^S240/244. Surprisingly, it also triggers up-regulation of total HER3 and/or pHER3^Y1289 levels. In HER2-overexpressing cells, inhibition of PI3K is followed by up-regulation of expression and phosphorylation of multiple receptor tyrosine kinases, including HER3. Knockdown of FoxO1 and FoxO3a transcription factors prevents the induction of HER3, InsR, IGF1R, and FGFR2 mRNAs upon inhibition of PI3K. In HER2⁺ cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhances XL147-induced cell death and inhibition of pAKT and pS6.

생체 내(In Vivo)

Athymic mice with BT474 xenografts are randomly treated with XL147 analogue, lapatinib, trastuzumab, or this compound plus each HER2 antagonist. Each monotherapy significantly inhibtis tumor growth with trastuzumab being the only agent that induced a complete tumor regression in one of eight mice. Both combinations are superior to the respective drugs given alone. Notably, the combination of trastuzumab and this chemical, but not lapatinib and XL147, induces a complete tumor response in three of eight mice. There is no marked drug-related toxicity in any of the treatment arms. The combination of this compound plus trastuzumab prevents pHER3 more potently than any of the other treatments. In good agreement with differences in tumor growth among treatment arms, nuclear pAKT is lower in tumors treated with XL147 plus lapatinib or this chemical plus trastuzumab compared with tumors treated with single agents. Of all three single drugs, this compound is the only one shown statistically to repress nuclear pAKT levels. There are no detectable changes in cytoplasmic pAKT levels. Combined inhibition of HER2 and PI3K in HER2-dependent xenografts is required to maximally inhibit signaling output of the PI3K/AKT pathway.

프로토콜 (참조)

세포 분석:^{^[2]}	세포주 BT474 and HCC1937 cells 농도 0-20 μM 배양 시간 72 hours 방법 Cells including BT474, HCC1937 et al. are seeded in 100-mm dishes in media containing 2.5% FBS with or without this compound. After 3 days, detached and adherent cells are pooled, ﬁxed, and labeled with propidium iodide by using the APO-BrdU kit. Labeled cells are analyzed using the Becton Dickinson FACSCalibur system.
동물 연구:^{^[2]}	동물 모델 Athymic female mouse bearing BT474 cells 용량 100 mg/kg 투여 Orogastric gavage

세포 분석:^{^[2]}

세포주
BT474 and HCC1937 cells
농도
0-20 μM
배양 시간
72 hours
방법
Cells including BT474, HCC1937 et al. are seeded in 100-mm dishes in media containing 2.5% FBS with or without this compound. After 3 days, detached and adherent cells are pooled, ﬁxed, and labeled with propidium iodide by using the APO-BrdU kit. Labeled cells are analyzed using the Becton Dickinson FACSCalibur system.

동물 연구:^{^[2]}

동물 모델
Athymic female mouse bearing BT474 cells
용량
100 mg/kg
투여
Orogastric gavage

참조

#
https://pubmed.ncbi.nlm.nih.gov/21368164/

고객 제품 검증

: Dr. Zhang of Tianjin Medical University ,

: , , Dr. Chunrong Yu of RoswelI Park Cancer Institute

Selleck's XL147 analogue 인용됨 18 출판물

MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB [ Autophagy, June 15, 2012, 903-914]	PubMed: 22576015
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB [ Autophagy, June 1, 2012, 903-914]	PubMed: 22576015
Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo [ PLoS One, August 21, 2014, e105280]	PubMed: 25144531
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258]	PubMed: 35207746
Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome [ Hum Cell, 2022, 10.1007/s13577-022-00671-y]	PubMed: 35118583
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ Journal of Personalized Medicine, 2022, 258]	PubMed: 35207746
Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00579-z]	PubMed: 34304386
Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00639-4]	PubMed: 34731453
Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma [ Hum Cell, 2021, 34(6):1911-1918]	PubMed: 34383271
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma [ Hum Cell, 2020, 10.1007/s13577-020-00420-z]	PubMed: 32870449

반품 정책
Selleck Chemical의 무조건 반품 정책은 고객에게 원활한 온라인 쇼핑 경험을 보장합니다. 구매에 어떤 식으로든 불만족하시면, 수령일로부터 7일 이내에 모든 품목을 반품하실 수 있습니다. 제품 품질 문제(프로토콜 관련 문제 또는 제품 관련 문제)가 발생하는 경우, 원래 구매일로부터 365일 이내에 모든 품목을 반품하실 수 있습니다. 제품 반품 시 아래 지침을 따르십시오.

배송 및 보관
Selleck 제품은 실온에서 운송됩니다. 실온에서 제품을 받으셨더라도 안심하십시오. Selleck 품질 검사 부서에서 한 달간의 상온 보관이 분말 제품의 생물학적 활성에 영향을 미치지 않음을 확인하는 실험을 수행했습니다. 수령 후, 데이터시트에 설명된 요구 사항에 따라 제품을 보관하십시오. 대부분의 Selleck 제품은 권장 조건에서 안정적입니다.

인간, 수의학 진단 또는 치료 용도로 사용하지 마십시오.